10-K: FibroBiologics Reports Widening Losses, Nasdaq Listing Concerns

FibroBiologics, a clinical-stage biotech, reported increased net losses and a going concern doubt for 2025, while advancing its fibroblast-based therapies and addressing Nasdaq listing compliance.

Summary

• FibroBiologics is a clinical-stage biotechnology company developing fibroblast-based therapies for chronic diseases including wound healing, multiple sclerosis (MS), degenerative disc disease, psoriasis, and potential human longevity applications.
• The company reported a net loss of $18.6 million for the year ended December 31, 2025, an increase from $11.2 million in 2024, with an accumulated deficit of $54.2 million.
• Cash and cash equivalents stood at $4.9 million as of December 31, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern, dependent on raising additional capital.
• CYWC628 for wound healing has completed IND-enabling preclinical studies and is set to begin a Phase 1/2 clinical trial in Australia in Q1 2026.
• CYMS101 for Multiple Sclerosis completed a Phase 1 study in Mexico with 5 participants, showing no adverse events and general improvement in PASAT and Nine-Hole Peg tests, with plans to file a U.S. IND for a Phase 1/2 trial in H1 2026.
• CybroCell for degenerative disc disease received FDA IND clearance in 2018, conditional on master cell bank approval, following positive rabbit model studies; the company plans to amend the IND to use fibroblast-derived chondrocyte spheroids.
• CYPS317 for psoriasis completed IND-enabling preclinical studies and an IND application for a Phase 1/2 clinical trial was filed with the FDA on December 30, 2025.
• The company holds 124 issued patents and 175 pending patent applications, with protections generally expiring between 2027 and 2043.
• FibroBiologics received delisting notifications from Nasdaq in July and August 2025 for failing to meet the minimum bid price ($1.00) and market value of publicly held shares ($35 million) requirements, but was granted an extension until April 13, 2026, to regain compliance.
• The company raised approximately $6.7 million in net proceeds from three registered direct offerings in November and December 2025.
• A material weakness in internal controls over financial reporting due to lack of segregation of duties was identified, with remediation plans underway.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a low sentiment score due to significant financial challenges, including widening losses and a going concern doubt, coupled with Nasdaq delisting concerns. While clinical progress is noted, the financial instability and operational risks overshadow these developments.

Positives

• Successful completion of IND-enabling preclinical studies for CYWC628 (wound healing) showing statistically significant acceleration in wound closure and improved quality of healed wounds.
• Initiation of a twelve-week Phase 1/2 clinical trial for CYWC628 in Australia in Q1 2026.
• Completion of a Phase 1 study for CYMS101 (Multiple Sclerosis) in Mexico with no adverse events and general improvement in neurological assessments (PASAT, Nine-Hole Peg test).
• FDA IND clearance received in 2018 for CybroCell (degenerative disc disease) based on positive animal study results, with plans to amend the IND to use an improved spheroid formulation.
• Filing of a Phase 1/2 IND application for CYPS317 (psoriasis) with the FDA on December 30, 2025, following positive preclinical data.
• Possession of a substantial intellectual property portfolio with 124 issued patents and 175 pending applications.
• Successful manufacturing of master cell bank and working cell bank for CYWC628, certified as released by the CDMO.

Negatives

• Incurred significant net losses of $18.6 million in 2025, an increase from $11.2 million in 2024.
• Accumulated deficit of $54.2 million as of December 31, 2025.
• Cash and cash equivalents of $4.9 million as of December 31, 2025, indicating a need for substantial additional funding.
• Substantial doubt about the company's ability to continue as a going concern.
• Received delisting notifications from Nasdaq for failing to meet minimum bid price and market value of publicly held shares requirements, though an extension was granted until April 13, 2026.
• Identified a material weakness in internal controls over financial reporting due to lack of segregation of duties.
• The market price of common stock has been highly volatile, ranging from $13.00 to $0.225 per share between March 2024 and February 2026.
• No composition of matter patents for CybroCell, which is generally considered the strongest form of intellectual property protection for drug products.

Risks

• Substantial doubt about the ability to continue as a going concern due to recurring operating losses and negative cash flows.
• Limited operating history and no product candidates approved for commercial sale, making future success and viability difficult to predict.
• Requirement for substantial additional capital to finance operations, with no assurance of availability on acceptable terms, potentially forcing delays or elimination of programs.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to product candidates on unfavorable terms.
• Lengthy, time-consuming, and unpredictable regulatory approval processes by the FDA and comparable foreign authorities.
• Potential for substantial delays or inability to complete development and commercialization of product candidates.
• Outcome of preclinical studies or early clinical trials may not be predictive of success in later clinical trials.
• Product candidates may cause adverse events, toxicities, or undesirable side effects, inhibiting regulatory approval or market acceptance.
• Even if approved, product candidates may not achieve adequate market acceptance among physicians, patients, and payors.
• Refrigerated product candidates require specific distribution, storage, handling, and administration, which could limit commercial opportunity.
• The novelty of cell therapy and the rigorous, complex, and uncertain regulatory landscape may impact approval time and cost.
• Competition from companies with greater financial, manufacturing, marketing, and technical resources.
• Material weakness in internal controls over financial reporting due to lack of segregation of duties, potentially affecting financial reporting accuracy and fraud prevention.
• Reliance on third parties (CROs, CDMOs, clinical investigators) to conduct studies and manufacturing, with risks of non-compliance, delays, or inadequate performance.
• Difficulties in enrolling patients in clinical trials could delay or adversely affect clinical development activities.
• Manufacturing cell therapy products is complex and subject to human and systemic risks, including production difficulties, sourcing issues, and supply constraints.
• Relationships with healthcare professionals and third-party payors are subject to federal and state healthcare fraud and abuse laws, false claims laws, and transparency laws.
• Significant product liability risks inherent in the development, testing, manufacturing, and marketing of therapeutic treatments.
• FDA and other regulatory authorities may not accept data from trials conducted outside their jurisdiction.
• Significant post-marketing regulatory requirements and oversight even if product candidates receive approval.
• Inability to protect intellectual property and proprietary technologies, or claims of infringement by third parties.
• Dependence on attracting and retaining highly skilled executive officers and employees.
• Difficulties in managing organizational growth.
• Failure to maintain compliance with Nasdaq continued listing requirements could result in delisting.
• Volatility in the market price of common stock.
• Existence of Series C Preferred Stock with super voting rights (13,000 votes/share) held by the CEO, potentially affecting common stockholders' voting power and control.
• Provisions in the certificate of incorporation and bylaws may delay or prevent a takeover.
• Exclusive forum provision in the certificate of incorporation may limit stockholders' ability to obtain a favorable judicial forum.
• Internal computer systems or those of third parties may fail or suffer security/data privacy breaches.
• Vulnerability to natural disasters, public health crises, or other business interruptions.
• Unfavorable global economic and geopolitical conditions could adversely affect business.
• Fluctuations in foreign currency exchange rates could negatively impact results of operations.
• Changes in tax law could adversely affect business and financial condition.
• Potential involvement in securities class action litigation.

Future Outlook

FibroBiologics expects to continue incurring significant net losses for the foreseeable future as it advances product candidates through clinical development, incurs manufacturing costs, seeks regulatory approvals, expands research and development, hires additional personnel, and builds commercialization infrastructure. The company plans to file a U.S. IND for a Phase 1/2 MS clinical trial in the first half of 2026 and will seek a strategic partner for CYMS101 development. Early-stage research programs for human longevity, certain cancers, and artificial pancreatic organoids will be accelerated as funding permits. The company anticipates relying on third parties for cell therapy manufacturing for the foreseeable future.

Management Comments

• Management concluded that there is substantial doubt as to whether the company can continue as a going concern for the twelve months following the issuance of the Annual Report.
• Management believes the early data for CYMS101 is promising and encouraging for a first-in-human use of fibroblast cells for a potential treatment of MS, but notes the number of patients was not high enough to infer statistical significance.
• Management plans to raise additional capital to fund operations through public or private equity offerings, debt financings, and/or potential collaborations and license arrangements or other sources.
• Management is responsible for assessing and managing cybersecurity risks and is informed by the IT MSP regarding cybersecurity matters.
• Management has assessed the effectiveness of internal control over financial reporting as of December 31, 2025, and concluded it was not effective due to a material weakness in segregation of duties.

Industry Context

StockSavvy.ai notes that FibroBiologics operates in the highly competitive and rapidly advancing biotechnology and pharmaceutical industries, specifically within the novel field of cell therapy. While the company's fibroblast-based approach offers potential advantages over traditional stem cell therapies (e.g., non-invasive harvesting, faster doubling time, superior immune modulation, cost-effectiveness), it faces significant challenges. The regulatory landscape for cell therapies is still developing and rigorous, posing higher risks and longer approval timelines compared to more established drug classes. The company's focus on chronic diseases with significant unmet needs, such as diabetic foot ulcers, MS, degenerative disc disease, and psoriasis, positions it in large and growing markets, but also against well-funded competitors like Biogen, Roche, Novartis, Sanofi, Johnson & Johnson, Mesoblast, Pfizer, and Eli Lilly, which have extensive experience and approved products. The company's early-stage pipeline and reliance on external funding and third-party manufacturing are common for clinical-stage biotechs but amplify financial and operational risks.

Comparison to Industry Standards

• FibroBiologics' fibroblast-based approach is positioned as favorable to stem cells due to non-invasive harvesting, faster doubling time, superior immune modulatory activity, and lower isolation/culture costs, differentiating it from companies primarily focused on mesenchymal stem cells (MSCs) like Mesoblast Limited.
• For wound healing, CYWC628's preclinical results showed statistically significant acceleration in wound closure and quality improvement compared to a marketed wound care product and control, suggesting potential competitiveness against existing treatments like Apligraf (neonatal keratinocytes/fibroblasts in bovine collagen), Grafix (cryopreserved human placental membrane), DermACELL (acellular dermal matrix), and TheraSkin (cryopreserved human skin allograft).
• In Multiple Sclerosis, CYMS101's Phase 1 study showed no adverse events and general neurological improvements, which is a positive initial safety signal compared to existing disease-modifying drugs from companies like Biogen, Roche, and Novartis, many of which have serious adverse effects and lack myelin/nerve regenerative capabilities.
• For degenerative disc disease, CybroCell's animal studies demonstrated differentiation of human dermal fibroblasts into chondrocyte-like cells, increased disc height, and reduced inflammatory markers, aiming to offer a less invasive, regenerative alternative to surgical interventions (discectomy, spinal fusion) and artificial disc replacements (e.g., activL Artificial Disc from Aesculap Implant Systems, LLC) or other tissue engineering approaches.
• The company's intellectual property portfolio of 124 issued patents and 175 pending applications is substantial for a company of its stage, providing a competitive moat, though the absence of composition of matter patents for CybroCell is a notable difference compared to the strong IP typically sought for novel drug products.

Management Changes

Corporate Governance

Legal Proceedings

• Currently not a party to any material legal proceedings, and no material legal proceedings are currently pending or threatened.

Related Party Transactions

• Paid an aggregate of $66,950 in 2025 to a member of the Board of Directors for strategic advisory services, including support for finance and capital raising activities, pursuant to a consulting agreement effective May 15, 2025.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from future equity offerings and convertible debt conversions. The super voting rights of Series C Preferred Stock held by the CEO could limit common shareholders' influence. Nasdaq delisting concerns pose a risk to liquidity and stock price. The going concern doubt presents a fundamental risk to investment.
• **Employees**: The company's growth plans include hiring additional personnel, which could create new opportunities. However, the financial instability and need for capital raises could create uncertainty regarding job security and long-term prospects.
• **Customers/Patients (future)**: Potential for new fibroblast-based therapies to address unmet medical needs in chronic diseases like wound healing, MS, degenerative disc disease, and psoriasis. Delays in clinical trials or regulatory approval would delay access to these potential treatments.
• **Creditors**: The 'going concern' doubt and recurring operating losses indicate increased risk for creditors, as the company's ability to meet its financial obligations is uncertain without further capital raises.
• **Suppliers/Partners**: Reliance on third-party CDMOs and CROs means their operational stability and compliance are critical to the company's development timelines. Delays or issues with these partners directly impact FibroBiologics' progress.

Next Steps

• Initiate a twelve-week Phase 1/2 clinical trial in Australia for CYWC628 (wound healing) in the first quarter of 2026.
• Conduct further research to more fully characterize the mode of action of fibroblasts in oligodendrocyte expansion for CYMS101.
• File an IND application for a Phase 1/2 clinical trial relating to MS in the United States in the first half of 2026.
• Seek a strategic partner to collaborate on the development of CYMS101.
• Work to amend the IND clearance with the FDA for CybroCell to replace single-cell fibroblasts with fibroblast-derived chondrocyte spheroids.
• Determine a timeline for the CybroCell clinical trial through discussions with the FDA.
• Design and conduct preclinical studies to demonstrate thymic or splenic involution reversal in animal models for CYTER915 (human longevity).
• Accelerate early-stage research programs for human longevity, certain cancers, and artificial pancreatic organoids as funding allows.
• Evaluate the feasibility of building an own cGMP manufacturing facility or continuing to outsource manufacturing if product candidates receive marketing approval.
• Add additional accounting staff, strengthen segregation of duties, and implement initiatives to improve internal controls over financial reporting.
• Actively monitor the closing bid price of common stock, market value of publicly held shares, and stockholders' equity to regain and maintain Nasdaq compliance by April 13, 2026.

Key Dates

Recommendation

The filing reveals a company in a precarious financial position, marked by widening net losses, a significant accumulated deficit, and critically low cash reserves, leading to a 'substantial doubt about our ability to continue as a going concern.' This fundamental uncertainty is compounded by ongoing Nasdaq delisting concerns, which threaten the stock's liquidity and market visibility. While there is clinical progress with several product candidates, the financial instability and the need for substantial additional capital, likely through dilutive offerings, present an overwhelming risk to current and prospective investors. The material weakness in internal controls further adds to governance concerns. Given these severe financial and operational headwinds, a 'strong sell' recommendation is warranted for any existing holdings, and new investment should be avoided.

Keywords

FibroBiologics, FBLG, Biotechnology, Cell Therapy, Fibroblast-based therapies, Wound Healing, Multiple Sclerosis, Degenerative Disc Disease, Psoriasis, Human Longevity, Clinical-stage, SEC Filing, 10-K, Nasdaq, Biologics License Application, IND, Preclinical Studies, Clinical Trials, Orphan Drug, Intellectual Property, Corporate Governance, Going Concern, Capital Raise